Exclusive Lev Facher STAT Plus: Biden drug czar: ‘All options are on the table’ for expanding methadone access
Exclusive Lev Facher STAT Plus: Biden drug czar to summon naloxone makers to White House to discuss pricing
First Opinion Stacey McKenna Fear-based messaging doesn’t stop drug use. But it does make things worse
Health Lev Facher Black patients far less likely to receive key opioid addiction medication, study finds
Health Lev Facher STAT Plus: DEA will delay telemedicine restrictions for buprenorphine, Adderall, and other drugs
Health Carla K. Johnson — Associated Press Babies born to opioid users have shorter hospital stays with parental involvement: study
Health Tech Mario Aguilar STAT Plus: Once bullish on digital health, Orexo hits a wall on reimbursement
Health Lev Facher STAT Plus: Pennsylvania set to ban supervised drug use sites, in setback for harm reduction
First Opinion Jonathan JK Stoltman and Mishka Terplan OTC naloxone is a baby step toward making the life-saving medication accessible
Health Lev Facher STAT Plus: White House designates xylazine, better known as ‘tranq,’ as an emerging drug threat
Politics Sarah Owermohle STAT Plus: A controversial hire at Arnold Ventures raises questions about the donor’s stance on addiction
Special Report Lev Facher STAT Plus: How the drug industry uses fear of fentanyl to extract more profit from naloxone
Health Lev Facher STAT Plus: HHS secretary signals support for new restriction on addiction treatment
Health Lev Facher Amid fentanyl crisis, first-of-its-kind study to evaluate expanded methadone access
First Opinion Howard K. Koh and Michael Fiore Tobacco companies pledge ‘harm reduction’ but are doing the opposite
Health Lev Facher FDA advisers recommend approval of over-the-counter naloxone to fight opioid overdose
First Opinion Beth S. Linas and Benjamin P. Linas The X-waiver for buprenorphine prescribing is gone. It’s time to spread the word
First Opinion Nora D. Volkow Pregnant people with substance use disorders need treatment, not criminalization